MetaVia Inc. (MTVA)
NASDAQ: MTVA · Real-Time Price · USD
1.610
+0.035 (2.22%)
Mar 31, 2025, 3:43 PM EDT - Market open
MetaVia Employees
MetaVia had 9 employees as of December 31, 2024. The number of employees increased by 1 or 12.50% compared to the previous year.
Employees
9
Change (1Y)
1
Growth (1Y)
12.50%
Revenue / Employee
n/a
Profits / Employee
-$3,065,778
Market Cap
13.93M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
MTVA News
- 11 days ago - MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 2 months ago - MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference - PRNewsWire
- 4 months ago - NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases - PRNewsWire
- 4 months ago - NeuroBo Pharmaceuticals to Participate in Investor Conferences in November - PRNewsWire
- 5 months ago - NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 5 months ago - NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH - PRNewsWire
- 6 months ago - NeuroBo Pharmaceuticals to Participate in Investor Conferences in October - PRNewsWire
- 6 months ago - NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity - PRNewsWire